B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20

Futu NewsDec 21 03:31 · Ratings

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

TipRanksDec 21 02:41 · Ratings

The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.

The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.

wallstreetcnDec 20 19:49

Express News | Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket

BreakingsDec 20 19:04

Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

BreakingsDec 20 19:03

Hims & Hers Shares Tumble as FDA Resolves Obesity Drug Shortage

InvestingDec 19 22:24